In short
This article explores the use of Emedastine Difumarate Eye Drops in clinical trials for the treatment of allergic rhinitis. The study focuses on comparing the efficacy of allergen-specific immunotherapy with conventional drug treatments, including Emedastine, in managing symptoms of seasonal allergic rhinitis caused by Artemisia pollen.
At a glance
- Study Type
- Randomized, Open-label, Multicentered trial
- Participants
- 150 subjects with allergic rhinitis caused by Artemisia pollen
- Treatment Groups
- 1. Sublingual Immunotherapy group; 2. Drugs treatment group (including Emedastine Difumarate Eye Drops)
- Emedastine Usage
- Once daily, as needed for symptom relief
- Primary Outcomes
- 1. Change in symptom scores; 2. Change in quality of life scores
- Secondary Outcomes
- 1. Daily medication score; 2. Combined symptom and medication score; 3. Health economics evaluation; 4. Adverse events; 5. Biomarker changes; 6. Cytokine expression changes; 7. Nasal cavity measurements; 8. IgE level changes
- Study Duration
- 3 years with multiple assessment points
What is Emedastine?
Emedastine, specifically Emedastine Difumarate, is a medication used in the form of eye drops to treat symptoms of allergic rhinitis. Allergic rhinitis is a condition where your nose becomes inflamed due to an allergic reaction, often causing symptoms like sneezing, runny nose, and itchy eyes.
How is Emedastine Used?
Emedastine Difumarate is administered as eye drops. In the clinical trial described, it was used once a day as needed to relieve allergy symptoms. However, always follow your doctor's instructions on how often to use the medication.
Conditions Treated by Emedastine
Emedastine is primarily used to treat symptoms associated with allergic rhinitis. This condition is described in the clinical trial as "a noninfectious inflammatory disease of the nasal mucosa mediated by immunoglobulin E (IgE) after exposure to allergens." In simpler terms, it's an allergic reaction in your nose caused by things like pollen, dust, or pet dander.
Clinical Trial Information
A clinical trial (NCT05318157) was conducted to study the effectiveness of allergen-specific immunotherapy for allergic rhinitis caused by Artemisia pollen. While Emedastine was not the main focus of this study, it was used as part of the treatment regimen.
The trial involved 150 subjects with allergic rhinitis caused by Artemisia pollen. Participants were divided into two groups: one receiving immunotherapy and another receiving conventional drug treatment, which included Emedastine Difumarate Eye Drops.
Other Treatments Used in Combination
In the clinical trial, Emedastine Difumarate Eye Drops were used in combination with other medications to manage allergy symptoms. These included:
- Clarityne: An antihistamine that helps reduce allergy symptoms like sneezing and itching
- Rhinocort: A nasal spray containing corticosteroids to reduce inflammation in the nose
These medications were permitted to be used once a day, as needed, to relieve allergy symptoms.
Effectiveness of Emedastine
While the clinical trial doesn't provide specific information about the effectiveness of Emedastine alone, it was included as part of the conventional drug treatment for allergic rhinitis. The study measured several outcomes to assess the effectiveness of the treatments, including:
- Changes in symptom scores
- Quality of life improvements
- Daily medication usage
- Combined symptom and medication scores
These measurements were taken at various points throughout the study, including at baseline, during the high pollen seasons for three years, and at the end of the two-year treatment period. The results of these measurements would help determine how effective the treatment regimen, including Emedastine, was in managing allergic rhinitis symptoms.